Scynexis Stock Today
| SCYX Stock | USD 1.12 0.05 4.27% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Scynexis is trading at 1.12 as of the 16th of February 2025; that is 4.27 percent decrease since the beginning of the trading day. The stock's open price was 1.17. Scynexis has about a 37 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of January 2025 and ending today, the 16th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of May 2014 | Category Healthcare | Classification Health Care |
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey. Scynexis operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 37.94 M outstanding shares of which 830.08 K shares are at this time shorted by private and institutional investors with about 2.93 trading days to cover. More on Scynexis
Moving against Scynexis Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Scynexis Stock Highlights
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsScynexis can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Scynexis' financial leverage. It provides some insight into what part of Scynexis' total assets is financed by creditors.
| |||||
Scynexis (SCYX) is traded on NASDAQ Exchange in USA. It is located in 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548 and employs 29 people. Scynexis is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 42.5 M. Scynexis conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 37.94 M outstanding shares of which 830.08 K shares are at this time shorted by private and institutional investors with about 2.93 trading days to cover.
Scynexis currently holds about 96.09 M in cash with 60.16 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Scynexis Probability Of Bankruptcy
Ownership AllocationScynexis shows a total of 37.94 Million outstanding shares. 30% of Scynexis outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Scynexis Ownership Details
Scynexis Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-09-30 | 107.3 K | |
| Empowered Funds, Llc | 2024-12-31 | 102.2 K | |
| Northern Trust Corp | 2024-09-30 | 101.1 K | |
| Wealth Effects Llc | 2024-12-31 | 94 K | |
| Nierenberg Investment Management Co | 2024-09-30 | 75.6 K | |
| Lpl Financial Corp | 2024-09-30 | 75.5 K | |
| Bank Of New York Mellon Corp | 2024-12-31 | 35.1 K | |
| Bleakley Financial Group Llc | 2024-12-31 | 20 K | |
| Chicago Partners Investment Group Llc | 2024-12-31 | 17.9 K | |
| Federated Hermes Inc | 2024-09-30 | 3.6 M | |
| Kingdon Capital Management Llc | 2024-09-30 | 2.2 M |
Scynexis Historical Income Statement
Scynexis Stock Against Markets
Scynexis Corporate Management
| Debbie Etchison | Executive Communications | Profile | |
| Scott JD | Chief Secretary | Profile | |
| Marco MD | Pres CEO | Profile | |
| Daniella Gigante | Vice Technology | Profile | |
| Christine MBA | Chief Officer | Profile | |
| David MD | Chief Officer | Profile |
Additional Tools for Scynexis Stock Analysis
When running Scynexis' price analysis, check to measure Scynexis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scynexis is operating at the current time. Most of Scynexis' value examination focuses on studying past and present price action to predict the probability of Scynexis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scynexis' price. Additionally, you may evaluate how the addition of Scynexis to your portfolios can decrease your overall portfolio volatility.